Decellularized muscle matrices are provided for use as implants and grafts to repair, regenerate, supplement, reinforce and replace muscle tissue. The decellularized muscle matrices are derived from muscle tissue having preserved extracellular matrix components, retained muscle-forming potential, and from which immunogenic components have been removed. The decellularized muscle matrices are produced in various physical forms and combinations. Methods for making and using the decellularized muscle matrices are also provided.

The present invention provides compositions and methods that modulate the immune system in a subject.

Provided herein is a drug delivery system comprising: a. substrate; b. a plurality of components combined with the substrate to form the drug delivery system; wherein at least one components comprises a bioabsorbable polymer and at least one other component comprises one or more active agents; wherein at least part of the active agent is in crystalline form.

Various aspects of the present disclosure provide compositions including a water-insoluble therapeutic agent and a gallate-containing compound. Other aspects provide methods of using such compositions.

A method for depositing a coating comprising a polymer and at least two pharmaceutical agents on a substrate, comprising the following steps: providing a stent framework; depositing on said stent framework a first layer comprising a first pharmaceutical agent; depositing a second layer comprising a second pharmaceutical agent; Wherein said first and second pharmaceutical agents are selected from two different classes of pharmaceutical agents.

Expanded, nanofiber structures are provided as well as methods of use thereof and methods of making.

The present invention relates to biomaterials that interact with and regulate immune functions, as well as implantable materials and devices. In one embodiment, the present invention provides an implantable medical device comprising a biomaterial coated with one or more CD200 molecules. In another embodiment, the present invention provides a method of treating inflammation by administering a composition comprising one or more biomaterials that inhibit immune reactivity.

A medical assembly is disclosed comprises a stent and a catheter having a balloon, wherein the coefficient of friction and/or the adhesion at the stent/balloon interface are reduced.

A medical device is disclosed, which is capable of treating cardiac insufficiency, on a causal therapy basis. The medical device is a heart harness composed of a porous hollow structure. A method of treating a heart disease includes applying the medical device as above to a heart of a subject in need thereof.

This invention provides solid substrates for mitigating or preventing cell or tissue adherence and/or vascularization, which solid substrates comprise a marine organism skeletal derivative and are characterized by a specific fluid uptake capacity value of less than 40%, processes for selection of the same and applications of the same. This invention also provides solid substrates for mitigating or preventing cell or tissue adherence and/or vascularization, which solid substrates are characterized by having a contact angle value of more than 60 degrees, when in contact with a fluid. This invention also provides solid substrates for mitigating or preventing cell or tissue adherence and/or vascularization, which solid substrate is characterized by a minimal surface roughness (Ra) or substantial surface smoothness, as measured by scanning electron microscopy or atomic force microscopy. The invention also provides processes for selection of an optimized coral-based solid substrate.